The study presented here is the first to directly compare efficacy
and safety/tolerability of two DPP-4 inhibitors, namely
vildagliptin and sitagliptin, in patients with type 2 diabetes and
severe RI. The overall HbA1c lowering effect was similar for
both drugs and both drugs were well tolerated.
Both drugs in this study were used at their expected maximal
effective and recommended doses (in accordance with